spacer
home > ebr > autumn 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Fewer than 10 advanced therapy medicinal products (ATMPs) are currently licensed for use in Europe. The R&D pipeline of early stage ATMP candidates is strong at present, but the manifold challenges (including chemistry, manufacturing and controls, clinical trials, and complex regulatory pathways) to bringing these potentially transformational therapies to market are such that it will take considerable time before their full potential in healthcare is realised. In this autumn 2018 edition of EBR, The Christie Hospitalís Dr Fiona Thistlethwaite and Aptus Clinicalís Dr Ian Thomas introduce the Innovate UK-funded iMatch consortium of clinical and commercial researchers, who will aim to overcome some of the key barriers to successful progression of ATMPs and their scale-up for a range of chronic debilitating conditions (page 14). A major therapeutic focus of ATMP development is oncology, spearheaded by the recently approved Kymriah, for acute B-cell lymphoblastic lymphoma, and Yescarta, for non-Hodgkin lymphoma, from Novartis and Kite/ Gilead respectively. These classes of drug are one of the precision therapies included in N-of-Oneís Dr Kathryn D Bungartzís comprehensive summary of the current cancer therapy innovation landscape (page 56). So too are antibody-drug conjugates, the challenges in production of which and the potential means to circumvent are discussed by the Sanofi and Merck Group teams (page 80).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Case Study: Getting the Clientís Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmedís performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

4-6 December 2018, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy will provide you with the latest advice for transforming innovative research to prosperous cell & gene therapy manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement